TAILORx Tissue Bank
Breast Cancer Bank of Tissue From Trial Assigning Individualized Options for Treatment (TAILORx Tissue Bank)
1 other identifier
observational
600
1 country
12
Brief Summary
This is an exploratory, translational, non-interventional and multi-centre biobank. The aim of the development of such a biobank is to identify potential biomarkers that are indicative of disease relapse.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2013
Longer than P75 for all trials
12 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2013
CompletedFirst Submitted
Initial submission to the registry
January 24, 2014
CompletedFirst Posted
Study publicly available on registry
January 31, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2031
ExpectedDecember 19, 2025
December 1, 2025
7 years
January 24, 2014
December 15, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Disease relapse, endocrine and/or chemotherapy resistance prognosis
A biobank, TMAs and full face sections, will allow for the identification of candidate/novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance
For duration of follow up, expected 10 years
Secondary Outcomes (1)
Signature/biomarkers
For the duration of follow up, expected 10 years
Study Arms (1)
TAILORx ICORG 06-31
Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available
Eligibility Criteria
The study population will consist only of patients that participated in the TAILORx ICORG 06-31 trial. These patients must have participated in trial arms relevant to ICORG 06-31 study and have adequate tumour tissue available.
You may qualify if:
- Patients that were registered with the ICORG 06-31 TAILORx trial and participated in trial arms
- Patients with adequate tumor tissue available
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (12)
Bons Secours Hospital
Cork, Ireland
Cork University Hospital
Cork, Ireland
Letterkenny General Hospital
Donegal, Ireland
Adelaide and Meath National Children's Hospital Tallaght
Dublin, 24, Ireland
St Vincent Universtiy Hospital
Dublin, 4, Ireland
St James Hospital
Dublin, 8, Ireland
Beaumont Hospital
Dublin, 9, Ireland
Mater Misericordiae University Hospital
Dublin, Ireland
Galway University Hospital
Galway, Ireland
Midwestern Regional Hospital
Limerick, Ireland
Sligo General Hosptial
Sligo, Ireland
Waterford Regional Hospital
Waterford, Ireland
Related Publications (1)
Lynch SM, Russell NM, Barron S, Wang CA, Loughman T, Dynoodt P, Fender B, Lopez-Ruiz C, O'Grady A, Sheehan KM, Fay J, Amberger-Murphy V, Saha A, Klinger R, Gonzalez CA, Al-Attar N, Rahman A, O'Leary D, Lanigan FT, Bracken AP, Crown J, Kelly CM, O'Connor DP, Gallagher WM. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors. Eur J Cancer. 2021 Jul;152:78-89. doi: 10.1016/j.ejca.2021.04.016. Epub 2021 Jun 2.
PMID: 34090143DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 24, 2014
First Posted
January 31, 2014
Study Start
December 1, 2013
Primary Completion
December 1, 2020
Study Completion (Estimated)
November 1, 2031
Last Updated
December 19, 2025
Record last verified: 2025-12